Fab I inhibitors
AssigneeAffinium Pharmaceuticals, Inc.
InventorsWalter J. Burgess, Dalia R. Jakas, William F. Huffman, William H. Miller, Kenneth A. Newlander, Mark A. Seefeld, Irene N. Uzinskas
Life of this patent
Estimating the term…
Abstract
Compounds are disclosed which are Fab I inhibitors and are useful in the treatment bacterial infections.
Claims4
A method of treating a S. aureus bacterial infection, in a subject in need thereof, comprising administering a therapeutically effective amount of the compound, (E)-N-methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide, or pharmaceutically acceptable salts thereof, to said subject.
The compound (E)-N-methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide or pharmaceutically acceptable salts thereof.
A composition comprising a pharmaceutically acceptable salt of (E)-N-methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.